Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine.
A recent clinical study demonstrated that sodium benzoate (SB), a prototype competitive d-amino acid oxidase inhibitor, was effective in the treatment of several symptoms, such as positive and negative symptoms, and cognitive impairment in medicated patients with schizophrenia. The objective of the study was to examine the effects of SB on behavioural abnormalities such as pre-pulse inhibition (PPI) deficits and hyperlocomotion in mice after a single administration of the N-methyl-D-aspartate (NMDA) receptor antagonist, phencyclidine (PCP). The effects of SB on behavioural abnormalities (PPI deficits and hyperlocomotion) in mice after PCP administration were examined. Furthermore, effects of SB on tissue levels of amino acids were also examined. A single oral dose of SB (100, 300, or 1000 mgkg) attenuated PPI deficits in mice after administration of PCP (3.0 mgkg, s.c.) in a dose-dependent manner. In contrast, L-701,324 (10 mgkg), an antagonist at the glycine site of the NMDA receptor, did not affect the effect of SB (1000 mgkg) on PCP-induced PPI deficits. Furthermore, a single oral dose of SB (1000 mgkg) significantly attenuated the hyperlocomotion in mice after administration of PCP (3.0 mgkg, s.c.). However, a single oral dose of SB (1000 mgkg) caused no changes to D-serine levels in plasma or in the frontal cortex, hippocampus, and striatum of these animals. This study suggests that SB induced antipsychotic effects in the PCP model of schizophrenia, although it did not increase D-serine levels in the brain.